Wai Lo

United States UConn

Article

Commented on JIP3 interacts with dynein and kinesin-1 to regulate bidirectional organelle transport
The findings highlight the RH1 domains of JIP3 as critical sites for motor protein interaction, underscoring the complex interplay between JIP3-bound dynein and kinesin-1 in the bidirectional transport of organelles. This study sheds light on the molecular mechanisms by which JIP3 coordinates motor proteins to prevent lysosome accumulation in neurons, offering insights into the broader understanding of axonal transport and its implications for neurobiology.

Journal

Commented on JOURNAL OF CATALYSIS
The JOURNAL OF CATALYSIS is recruiting volunteer reviewers for their journal, please register your name in this site: https://www.sciencedirect.com/journal/journal-of-catalysis/about/volunteer-to-review

Journal

Commented on Biomedicines
Biomedicines is recruiting volunteer reviewers. Reviewers are responsible for regularly providing timely, high-quality reports on manuscripts submitted to the journal. More information about the role is available at: https://www.mdpi.com/reviewers.

Journal

Commented on RSC Advances
Royal Society of Chemistry is looking for volunteer reviewers to review their submissions. Please register here: https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/reviewer-information/how-to-become-a-reviewer/

Journal

Commented on BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Biochemical and Biophysical Research Communications is recruiting volunteer to review their papers. You can register your information here: https://www.sciencedirect.com/journal/biochemical-and-biophysical-research-communications/about/news

Funding

Commented on International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)
Looks like there is another call for minority and underfunded universities or colleges.

Article

Commented on Robotics: Science and Systems
The conference Robotics: Science and Systems was held at the University of Washington in Seattle, from June 28 to July 1, 2009. More than 300 international researchers attended this single-track conference to learn about the most exciting robotics research and most advanced robotic systems. The program committee selected 39 papers out of 154 submissions. The program also included invited talks. The plenary presentations were complemented by workshops.

Journal

Commented on Foundations and Trends in Machine Learning
This ranks the top AI related journal. Current impact factor is 32.8. Published by NOW Publishing LLC.

Journal

Commented on Nature Machine Intelligence
AI / machine learning related journal published by Nature. They launched it in 2019 but the current impact factor is already 23.8 and it is rising. I feel it has the potential to beat the Nature-Nature.

Article

Commented on Tctex-1, a Novel Interaction Partner of Rab3D, Is Required for Osteoclastic Bone Resorption
The interaction between dynein light chain Tctex-1 and osteoclast bone resorption regulator Rab3D plays a key role in modulating the bone-resorbing activities of osteoclasts.

Hub

Commented on AI in education, teaching, learning
AI allows students at all grade levels to interact with the world around them, learn about themselves and other people and explore STEM in new ways.

Webinar

Commented on Fighting off journal rejections on the path to manuscript acceptance
Wow, this is one of the most important areas for academic publication. Look forward to the webinar.

Article

Commented on Tirzepatide: First Approval
Tirzepatide (Mounjaro™) is a novel medication developed by Eli Lilly that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to improve glycemic control in adults with type 2 diabetes mellitus (T2DM), among other potential applications. It functions by stimulating insulin secretion, decreasing glucagon secretion, delaying gastric emptying, and enhancing satiety. After its first approval in the USA in May 2022 for T2DM, tirzepatide is also being explored for treating obesity, heart failure, and other conditions, with ongoing trials in various stages of development. This drug makes Eli Lily's stock value went up a lot.

Article

Commented on Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics
its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial.